Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency

AIM: Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron‐deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR‐HF and CONFIRM‐HF pooled analysis explored the likelihood of individual improvement or...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Javed, Khan, Muhammad Shahzeb, Friede, Tim, Jankowska, Ewa A., Fabien, Vincent, Goehring, Udo‐Michael, Dorigotti, Fabio, Metra, Marco, Piña, Ileana L., Coats, Andrew J.S., Rosano, Giuseppe, Comin‐Colet, Josep, Van Veldhuisen, Dirk J., Filippatos, Gerasimos S., Anker, Stefan D., Ponikowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Iron Deficiency
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313582/
https://www.ncbi.nlm.nih.gov/pubmed/35279929
http://dx.doi.org/10.1002/ejhf.2478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313582/
https://www.ncbi.nlm.nih.gov/pubmed/35279929
http://dx.doi.org/10.1002/ejhf.2478

Ejemplares similares